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Neural stimulation is a powerful tool to study brain physiology and an effective treatment for many
neurological disorders. Conventional interfaces use electrodes implanted in the brain. As these are often
invasive and have limited spatial targeting, they carry a potential risk of side-effects. Smaller neural
devices may overcome these obstacles, and as such, the field of nanoscale and remotely powered neural
stimulation devices is growing. This review will report on current untethered, injectable nanomaterial
technologies intended for neural stimulation, with a focus on material-tissue interface engineering. We
will review nanomaterials capable of wireless neural stimulation, and discuss their stimulation mech-
anisms. Taking cues from more established nanomaterial fields (e.g., cancer theranostics, drug delivery),
we will then discuss methods to modify material interfaces with passive and bioactive coatings. We will
discuss methods of delivery to a desired brain region, particularly in the context of how delivery and
localization are affected by surface modification. We will also consider each of these aspects of nanoscale
neurostimulators with a focus on their prospects for translation to clinical use.
© 2021 Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The field of neurostimulation has evolved significantly in the
past decades with many alternatives to traditional clinical tools. For
neurological disorders, the efficacy of preventive and drug-based
treatments is limited, mainly due to blood-brain barrier perme-
ability issues [1,2]. Instead, non-pharmacological approaches to
modulate pathological neural activity have emerged, such as
transcranial magnetic stimulation (TMS) [3], deep-brain stimula-
tion (DBS) [4], or focused ultrasound (FUS) [5] as one of the newest
strategies.
Among key considerations when selecting the best modulatory
approach for a given application are the invasiveness of the tech-
nique, and the size and depth of the targeted area. As these vari-
ables are often conflicting, the most precise clinical treatments
available, such as DBS, are often also the most invasive. Even with
clinically-approved techniques like DBS and TMS, the exacting and Biosystems, Institute
logy, Karlsruhe, Germany.
ielski).
n open access article under the Cmechanism and extent of the electrical stimulation delivered re-
mains unclear (for review, see Refs. [6e8]). Additionally, the benefit
from interventions such as DBS must be weighed against risks and
side-effects common for all surgeries (e.g. infection, bleeding) and
those specific to neuroprosthetics (e.g. implant rejection, electrode
displacement, scarring) [9]. These risks limit their application to a
smaller patient population, and only those with severe impair-
ments [10]. To circumvent these risks, recent research into neural
devices has focused on smaller and remotely powered devices. In
particular, nanoscale, untethered, injectable materials are of
particular interest, as they can be delivered via minimally invasive
routes, and require no external wiring [11].
In pre-clinical research, several breakthroughs have been made
in recent years in order to potentially resolve some of these issues.
Minimally-invasive and cell-specific neurostimulation strategies
have been made possible thanks to the advent of opto-, thermo-
and chemogenetic tools [12e14]. Using ion channels responsive to
light, heat, or a specific chemical, these approaches allow the user
to selectively excite or inhibit neurons using the external stimulus.
While many fundamental neuroscience discoveries have been
made possible with these techniques in animal models, their
translation to human neurostimulation is fundamentallyC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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responsive elements, such as ion channels. Other issues are also
present, such as the temporal resolution of the techniques, which is
particularly slow in chemo- and thermogenetics. While opto-
genetics does work with high temporal precision, it still requires an
implanted device (e.g., fiber optic through a cranial window) or
equivalent means to deliver light to the target site [15]. Moreover,
these technologies carry the potential risk of altering the function
of intrinsic cellular machinery as a result of the insertion of large
numbers of foreign ion channels or pumps into the cellular mem-
brane [16].
Considering these limitations, the use of targeted, field-
transducing nanomaterials could complement the current clinical
and pre-clinical options available for neurostimulation. Several key
factors need to be addressed to realize them as neurostimulators:
non-invasive delivery of the nanomaterials to a desired brain
target, passive and active spatial selectivity of the nanomaterials’
localization, and the use of endogenous neuronal responsive mol-
ecules (e.g., mechano- or voltage-sensitive ion channels) which
interact with the nanomaterials transduced signal. In this review,
we will explore properties of nanomaterials that can be used for
neurostimulation, and how their material-to-tissue interfaces can
be engineered to address these core issues.
While nanoscale neurostimulators have different requirements
than other nanomedicines, the delivery and localization challenges
that they face inside of the body are similar. As such, the design of
nanoscale neurostimulators can take cues from nanomedicine as
they move towards clinical use. In cancer theranostics, for example,
nanomaterials are mainly used as environmentally-sensitive car-
riers of drugs or bioactive molecules, and can be actively or
passively targeted to tumor cells, while ignoring healthy tissue. For
neurostimulation, however, the nanomaterials themselves are
typically the cargo, so that they may act as nanotransducers of
external signals to modulate neuronal activity [17]. Similar prop-
erties have previously been exploited in clinically-approved ther-
mal ablation procedures with magnetic iron oxide particles for
some types of tumors [18]. Based on these transducing properties,
and using less extreme energy fields, nanomaterials can be used in
the brain to spatiotemporally stimulate or inhibit neuronal activity.
Several comprehensive reviews of recent advancements in cancer
applications of nanomaterials are already available, and can be used
as guides for similar constructs [19,20]. This review will focus on
exploring existing and potential combinations of surface coatings,
avenues for systemic delivery, and tissue targeting strategies with
untethered nanomaterials for applications in neural stimulation.
1.1. Conventional neurostimulation: strategies and limitations
Broadly, neuromodulation can be defined as the external
manipulation of neuronal activity through either physical or
chemical means, including electrode stimulation, as well as de-
livery of neuromodulatory drugs [21]. Within the broader scope of
neuromodulation, neurostimulation typically involves only elec-
trical alterations of neuronal activity in real time. While neuro-
stimulatory patterns can cause longer term neuromodulatory
effects, the signal transmission that neurostimulation requires
present a unique set of challenges when devices are remotely
powered.
In the clinic, electric and magnetic stimulation techniques can
treat some neurological conditions. Generally, electric stimulation
of neurons can be achieved either by direct contact between elec-
trodes and brain tissue (e.g., DBS; subdural grids of cortical elec-
trodes), or by an external electric field applied over the intact skin
(e.g., transcranial direct (tDCS), or alternating current stimulation
(tACS) [22]. Direct contact with electrodes normally requires1286minimally-invasive surgery involving a craniotomy and several
long-term implants, with all the associated risks of bleeding,
displacement, and infection [9]. Similar to tDCS and tACS, non-
invasive stimulation of neurons can be achieved transcranially
with a magnetic pulse (i.e. TMS) [3] or FUS [5]. While the non-
invasive electromagnetic strategies are able to bypass some of the
surgical issues, they are limited in terms of localizing the stimula-
tory output to a small brain region, reaching deeper areas, or
increasing intensity without over-stimulating more superficial
networks and tissues [23]. Additionally, the modulatory effects of
repetitive transcranial stimulation, both electric and magnetic, are
reported to be only transient for most patients and usually the ef-
fects wear off in less than a year [24,25].
While these modulatory options have been a significant
improvement of clinical care for neurological diseases, their
mechanisms of action are still poorly understood overall [7,22].
Gold-standard DBS treatments today still present considerable
technical issues (e.g., there is often a suboptimal control of the
overlap of the volume of tissue activation (VTA) with the desired
neuronal target [26,27]) as well as limitations in their therapeutic
effect (e.g., with current clinical approaches, it is hard to predict a
patient's response to DBS treatment beforehand [28] or selecting
the optimal brain region as a target [29]). Current non-invasive
options are also unable to appropriately target most deep brain
regions. The ability to manipulate specific neuronal networks has
been partially enabled pre-clinically using opto-, thermo- and
chemogenetic procedures, which have high spatial selectivity (for
review, see Ref. [11]).
Optogenetics can be broadly defined as genetic engineering of
neurons and other cells to enable photosensitivity via the expres-
sion of light-sensitive ion channels. Once stably expressed, a light
source (e.g., a fiber optic implant) can be used to modulate the
neuronal activity in the millisecond-scale [15,30]. Similar strategies
use thermosensitive ion channels instead, which are activated by
an increase in temperature after irradiation with light [12,31].
Chemogenetic strategies instead rely on the stable expression of a
modified ion channel designed to interact with an exogenous
molecule, which must be delivered to the modified neurons either
directly (e.g., intracranial injection) or systemically. Consequently,
the ability to observe neuronal modulation is constrained by the
pharmacological profile of the stimulating drug, usually yielding
relatively long response times (tens of seconds up to minutes)
versus that of optogenetics [32], while also presenting limited
spatial selectivity in the brain tissue when the drug is administered
systemically. While the benefit of using these techniques in
fundamental neuroscientific research is unquestionable, their
translation to the clinic is currently limited by several technical
challenges [33], including the frequent need for the targeted neu-
rons to be genetically modified in order to achieve stimulation.
2. Nanomaterials for neural stimulation
Nanomaterials have several applications in the nervous system
as drug delivery agents, immune modulators, and modulators of
neurodegenerative pathways [34,35]. In such nanomedicines, the
materials are often preprogrammed to carry out their role, and
require no external input following implantation into the body.
Conversely, nanomaterials for neurostimulation must act as trans-
ducers of an applied energetic field to achieve neural stimulation.
As such, the materials suitable for neurostimulation carry different
requirements and present different challenges than their neuro-
modulation counterparts.
The first step in the design of a neurostimulatory intervention
entails the selection of the applied stimuli and an appropriate
responsive nanomaterial. Organic and biological materials often do
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to yield strong transducing effects. While they still may be used in
the final nanostimulator design, the core transducing properties are
normally provided by a metallic or inorganic compound [36]. Cur-
rent wireless transduction methods include photothermal, photo-
mechanical, photoelectric, photochemical, magnetothermal,
magnetomechanical, magnetoelectric, or acoustoelectric in-
teractions [37e40]. A further consideration for the input signal and
transducing material is spatial selectivity. Depending on the
transduction mechanism, and the ability of the input signal to
penetrate tissue, spatial selectivity can be achieved either by
localized signals, or localization of the nanomaterial, but with
globally applied input stimulation. Fig. 1A shows a summary of
these transducing mechanisms, and Table 1 lists all current nano-
material designs used in neurostimulation. It should be noted that
in some experimental settings, more than one of these transduction
mechanisms may be present at once, as chemical, mechanical,
thermal, and electrostatic energies all converge at the nanoscale
[36]. The following section will therefore focus on the nano-
materials used for neurostimulation.2.1. Gold nanoparticles
Gold nanoparticles (AuNPs), mainly gold nanorods (AuNRs) and
nanospheres (AuNSs), have several applications in the biomedical
field as a photothermal material which also provides chemical and
physical stability, relatively low toxicity, and facile surface modifi-
cation [41]. Common synthesis techniques for AuNPs include
template-assisted gold deposition on a nanostructured surface,
electrochemical reduction of gold clusters on an anode, and seed-
growth mediated synthesis using nucleating and reducing agents.
For further details, see Refs. [42,43]. AuNP photothermal properties
are the result of the interaction of AuNPs with light in the visible or
near-infrared range. This interaction, which is highly dependent on
size and shape, produces a displacement of electrons in the mate-
rial from their equilibrium position, and creates a resonant
coherent oscillation known as the localized surface plasmon reso-
nance (LSPR). In many optical biological applications, the LSPR peakFig. 1. Overview of transducing mechanisms and their respective nanomaterials. A: G
Magnetothermal stimulation with magnetic nanoparticles; D: Acoustoelectric stimulatio
Reproduced with permission [14,39,45,77,89]. (For interpretation of the references to colou
1287is tuned in order to match the transparency range of biological
tissues (600e1200 nm) and provide controllable heating in the
immediate proximity of the AuNPs [41,44]. Since not all shapes
allow for this tuning, morphologies apt for optical approaches are
nanorods, nanoshells, nanostars and nanocages. Thus far, only
nanorods and nanospheres have been employed in neuro-
stimulation research (Fig. 1E) [38,45e49]. It should be noted that in
the case of [48], the reported effect on neurons is stimulation of cell
growth (e.g., neurite growth) and not the induction of action po-
tentials, which would be considered actual neurostimulation. In
addition to their photothermal capabilities, AuNPs can also exert
photomechanical effects via the formation of small bubbles which
open pores in the cell membrane, thanks to high energy output at
the LSPR peak [44,50]. The AuNPs themselves can be used as free-
standing devices [45,46,51] or be incorporated into nanostructured
electrode arrays, such as nanoelectronic threads [52].2.2. Carbon nanomaterials
Carbon nanomaterials present a wide diversity of structures,
morphologies, physical properties, and chemical reactivity
depending on the carbon allotrope used. While different synthesis
protocols are possible, chemical vapor deposition using hydrocar-
bons as fuel and metallic nanoparticles as catalysts is the most
common method [53,54]. Carbon nanomaterials can be nanotubes
(CNTs) (single-walled (SWCNTs) or multi-walled (MWCNTs)),
nanohorns, nanodiamonds, fullerenes, nano-onions, graphene dots
and other variants. This class of nanomaterials is a promising tool
for many biomedical applications in imaging, diagnostics, and
therapeutics [55,56]. Since carbon nanomaterials show low toxicity
with neurons in vitro [57e60] and remarkable physical and elec-
trical properties, their main research applications have been
directed towards neuroregeneration [55,61e63]. They have also
been used as interface materials for recording and stimulation of
neural tissue as components of a larger, tethered system [64,65].
However, most studies involving these nanomaterials are not
focused on the central nervous system (CNS), and have rarely been
tested in vivo [56]. Furthermore, novel carbon nanomaterials sucheneral transducing mechanism; B: Photoelectric stimulation with quantum dots; C:
n with boron nitride nanotubes; E: Photothermal stimulation with gold nanorods.
r in this figure legend, the reader is referred to the Web version of this article.)
Table 1


















Gold Nanorods Yong et al.,
2014 [46]










Optical Thermal N/A (commercial) In situ
injection































Optical Thermal Commercial streptavidin-conjugated NPs and
biotinylated antibodies
N/A N/A 50 nM to render
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Magnetic Electric BaTiO3 surface, no ligands In situ
injection
N/A 1 ml at 100 mg/ml Calcium imaging, c-
Fos expression, and
behavioral tests









Acoustic Electric DSPE-PEG-biotin dispersion þ streptavidin-
antibodies
N/A N/A Two doses (10 mg/
ml and 100 mg/ml)
Calcium imaging In vitro Immortalized
brain-derived
endothelioma
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recently developed and suggested for in vivo use, as they have
shown promising preliminary results in vitro for optical neuro-
stimulation [60].2.3. Iron oxide nanoparticles
While magnetic fields are able to penetrate deeply into the skull
and soft tissue, conventional transcranial approaches such as TMS
lack proper spatial resolution, and the power densities required can
yield significant off-target effects [23]. Paramagnetic and super-
paramagnetic nanoparticles such as iron-oxide nanoparticles
(IONPs) or ferritin-based constructs can transduce magnetic energy
into both mechanical and/or thermal energy, enabling neuro-
stimulation. Unlike TMS, this enables a local stimulation effect, but
in response to a global magnetic input signal (Fig. 1C) [66e71].
Magnetothermal heating is the result of rapid oscillations of an
alternating current (AC) magnetic field in the presence of magnetic
materials. Upon successive reorientations of the magnetic moment
along the field's direction, there is an hysteretic energy loss be-
tween themagnetic moment and themagnetic particle's lattice (for
a more thorough explanation see Ref. [72]). In order to produce
IONPs with an appropriate hysteretic-loss profile, synthesis pro-
tocols must control the magnetic anisotropy of the nanoparticles,
which is size-dependent. This can be achieved by combining ma-
terials with both soft and hard magnetic properties in core-shell
configurations. These can be produced with monodisperse sizes
while still maximizing their hysteretic-loss profile. Such IONPs can
be produced by thermal decomposition at high temperatures in
organic solvents [73].
Magnetomechanical energy transduction can also be employed
via mechanical realignment of a material's magnetic axis with an
applied magnetic field. Magnetic particles can be coupled to a
mechanosensitive ion channel, and an applied magnetic field can
exert torque sufficient to activate the channel [71]. Other mecha-
nisms have also been proposed involving the interactions between
the nanoparticles and weakly diamagnetic substances (e.g., bio-
logical molecules such as ferritin) within an aqueous solution.
However, the extent of the biological effects achievable with
magnetosensitive biomolecules has been previously disputed
[74,75] as there are fundamental objections that can be made
regarding the physical assumptions required for these effects to
occur. Particularly, the magnetism values suggested for para-
magnetic proteins are too weak to account for the reported mea-
surements by huge margins: from 5 to 10 log units.2.4. Multiferroic materials
A boron nitride nanotube (BNNT) is a structural equivalent of a
CNT with a portion of its C atoms substituted by alternating B and N
atoms to provide superior mechanical, chemical and electrical
properties. Common synthesis protocols which yield BNNTs use arc
discharge (high energy electrical ablation of reactive electrodes in
an inert-gas chamber), and ball-milling (nanomaterial powder is
milled by grinding balls), and chemical vapor deposition methods
(for further details, see Ref. [76]). These materials are piezoelectric
in nature, which means that their crystalline configuration can
discharge electric current upon application of a mechanical defor-
mation. Consequently, they are frequently used in combination
with ultrasounds, and the resulting electric effects can stimulate
neuronal cell growth. They have been also reported to show low
toxicity to cells when dispersed in glycol-chitosan or comparable
polymers (Fig. 1D) [77,78]. Importantly, this BNNT activity occurred
within the cytoplasm in contrast to outside the cell membrane,
D. Dominguez-Paredes, A. Jahanshahi and K.L. Kozielski Brain Stimulation 14 (2021) 1285e1297with important implications to the feasibility of the approach for
other stimulatory nanomaterials.
Like BNNTs, piezoelectric ceramics such as BaTiO3 nanoparticles
(BTNPs) can transduce applied ultrasound signals into electric
signals. Electric stimulation via BTNPs in vitro has been shown for
neuronal cell stimulation, alteration of neurite growth, and treat-
ment of glioblastomamultiforme [79,80]. In composite with BaTiO3
as a piezoelectric transducer, magnetostrictive CoFe2O4 nano-
particles present magnetoelectric behavior at room temperature
via strain-coupling of the two phases [81]. As magnetoelectric
materials undergo electric polarization in the presence of a mag-
netic field [82], magnetoelectric nanoparticles (MENPs) can be used
to electrically stimulate neurons. Synthesis can be achieved by a
two-step chemical procedurewhich combines co-precipitation and
sol-gel techniques [83]. Administration of MENPs to the brain has
been demonstrated via stereotactic injections, and magnetic
gradient targeting to the brain after intravenous delivery has been
suggested. Application of an external AC and DC magnetic field to
MENPs has demonstrated local and network neurostimulation in
mice [17]. Like other magnetically-stimulated materials, MENPs
provide localized stimulation via the material under application of
a global magnetic field.
2.5. Quantum dots
Quantum dots (QDs) are composite nanocrystals with a semi-
conductor core. While most synthesis protocols normally yield QDs
in organic solvents, there are alternatives to produce them inwater.
A synthesis protocol by Winter et al. yields mercaptoacetic-capped
CdS nanocrystals via arrested precipitation in aqueous solution
[84]. Their light absorbing and emitting features can be tuned by
selecting their size, shape, and core-shell compositions. QDs are
widely used as fluorescent probes in biology, with high quantum
efficiency and photostability. Furthermore, electrons or ‘holes’ may
escape the quantum confinement of the QDs under certain condi-
tions, generating an electric current, enabling their use as nano-
scale photoelectric stimulators [64,85e87]. While in vitro results
seem promising [88], some issues limit their clinical applicability.
Difficulties have been reported regarding high clearance via
endocytosis and non-specific binding to neurons in physiological
conditions when used as free standing devices [85]. This is due to
the particularly small size of QDs, which in some cases can get
below 5 nm [87]. Several groups have explored the use of QD films
to address some of these issues for in vitro setups, and have re-
ported different mechanisms of interaction (Fig. 1B) [86,87,89].
Other nanocrystal variants such as up-conversion nanoparticles
(UCNPs) [30], or holographically patterned photo-absorbers known
as PAINTS [90], while not strictly QDs, are also optical devices apt
for neurostimulation strategies which, due to their excitation using
light, are similarly designed to QD setups. It should be noted that
QDs and other light-stimulated particles will carry similar draw-
backs to optogenetic approaches, requiring localized stimulation
via an implanted light source.
3. Nanomaterial surface modification methods
While the choice of a particular nanomaterial-energy field
pairing will be done according to their fundamental physical in-
teractions as presented above (e.g., intensity, depth, side effects),
the final modulatory capabilities of the system will also depend on
its biological interactions. Such concerns include tissue targeting,
concentration, clearance, cell distance, etc. Thus, to elucidate how
the structural layout of a certain nanoscale neurostimulator will
condition the in vivo stimulatory possibilities, a thorough explora-
tion of surface chemistries and conjugation ligands is required for1290the abovementioned transducing materials. Many reviews of
nanomaterial surface chemistries already exist for in vivo applica-
tions such as cancer theranostics [41,91e93] and provide possible
avenues for surface modification of neurostimulatory nano-
materials. As such, this section will now discuss the surface mod-
ifications which have currently been applied to energy-transducing
nanomaterials for use in the nervous system.
While surface modification and bioconjugation of nano-
materials is a thoroughly studied field [19,93e95] [96], many
conjugation approaches are incompatible with materials used for
neurostimulation. Thus, this sectionwill provide a brief summary of
the surface modifications which can be used on the nanomaterials
of interest (Fig. 2). The relevant surface modifications will be dis-
cussed in terms of the stage of functionalization in which they are
employed (primary and secondary coatings) and the nature of the
chemical bond formed (covalent or non-covalent).
3.1. Primary and secondary surface modification
As nanoscale neurostimulators are frequently synthesized in
non-aqueous solutions, a primary coating is provided to solubilize
them and avoid toxicity or precipitation issues. Later, either by
substituting this primary layer or by adding a secondary chemistry,
additional ligands can be added, frequently aiming to provide more
bioactive functionalities. The first consideration in any conjugation
protocol will be the type of chemical residues present in the surface
of the nanomaterial. AuNPs and carbon nanomaterials present
elemental surfaces of pure atoms (gold, carbon) which may adopt
different physical topologies, but with generally the same chemical
reactivity. Other materials are formulated with oxygen atoms in the
form of oxides alongside their metallic elements (e.g., IONPs) or
mixtures of different elements (e.g., BNNTs, QDs) increasing the
options for primary surface modifications.
3.2. Covalent versus non-covalent surface modification
Nanomaterial surface modifications can be covalently or non-
covalently linked. Covalent linkages can provide more stable
modification, but limit the types of chemical interactions possible
with the transducing nanomaterial. This is the case, for example,
using silane chemistry on an oxygen-containing surface, on top of
which many additional well-known conjugation techniques can be
applied. Other covalentmodifications include conjugating bioactive
ligands such as proteins (e.g., antibodies) via nucleophilic sub-
stitutions, often achieved through standardized crosslinking pro-
tocols with (1-ethyl-3-(3-dimethylaminopropyl)carbodiimide/N-
hydroxysuccinimide (EDC/NHS) chemistry, or the widespread gold-
thiol chemistry strategies for AuNPs. Conversely, non-covalent
modifications require less precise matching of the material sur-
face with an appropriate chemistry. Hydrophilic, hydrophobic, and
amphipathic polymers (e.g., PEG, PAA, chitosan) or some surfac-
tants (phospholipids, CTAB) are commonly used both for colloidal
stability and as substrates for additional conjugations. Given how
non-covalent ligands form low-energy but high-number chemical
interactions (via hydrogen bonds, Van der Waals forces, etc.) their
stoichiometry and orientation in the final material is harder to
control, but they require milder reaction conditions than most
covalent modifications. Below, we will discuss covalent and non-
covalent surface modification methods used for neurostimulatory
nanomaterials.
3.3. Gold nanoparticles
Several protocols exist for the synthesis of both AuNRs [42] and
AuNSs [43]. Regarding cell toxicity, common protocols yield AuNPs
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cationic cetyltrimethylammonium bromide (CTAB), which is
known to be toxic both in vitro and in vivowhen solubilized [97]. To
avoid such issues, AuNPs can be readily modified via covalent re-
action with sulfur-containing molecules. Common toxicity issues
have been substantially solved by further modification/substitution
of the CTAB layer with thiolated polyethylene glycol, (SH-PEG),
phospholipids, silica shells, polyelectrolytes such as poly(4-
styrenesulfonic acid) (PSS) [98], polyacrylic acid (PAA) [99] or
oligo-ethylene glycol (OEG) [100] with silica coating by use of tet-
raethyl orthosilicate (TEOS) being a frequent choice for in vitro
neurostimulation [46,51].3.4. Carbon nanomaterials
CNTs are the main type of carbon nanomaterial researched for
biomedical purposes, including neuroscience [56,65]. Regardless, it
should be noted that given their mostly carbon composition, sur-
face modification options which can be used for most carbonFig. 2. Summary of surface functionalizations in neural stimulation nanomaterials. S
surface modification.
1291nanomaterials are quite similar, and usually involve the use of a
strong oxidant acid (e.g., nitric acid) to yield carboxyl residues on
top of which conjugate additional passive and/or bioactive moieties
[61,101,102] commonly by EDC/NHS chemistry.
On the other hand, BNNTs have been modified non-covalently
via organic polymers such as glycol-chitosan [77], amphiphatic
dendrimers [103], poly-ethyleneimine (PEI) or poly-L-lysine (PLL)
[104].3.5. Magnetic and multiferroic materials
In order to obtain monodisperse core-shell structured IONPs,
thermal decomposition at high temperatures (200-300 C) from
their metallic precursors (i.e. mix of iron (III), cobalt (II) and man-
ganese (II)) is performed in organic solvents. Transfer of the
resulting IONPs to an aqueous phase is often done by non-covalent
coating with an amphiphilic polymer such as dodecyl-grafted-
poly(isobutylene-alt-maleic anhydride/PMA) or PMA-shell for
short [69,70,73] which seems to perform well in vivo and can bechematic summarizing possible passive and bioactive ligands used for nanomaterial
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different approach was used by Gregurec et al. for their hematite
nanodiscs, where they initially covalently reduced them with a
surface of oleic acid, and later functionalized this surface non-
covalently with poly(maleic anhydride-alt-1-octadecene) (PMAO)
[71]. Noncovalent PEG coatings using PEG-oleic acid are also
commonly used to functionalize magnetic nanoparticles (Fig. 3E
and F) [105].
Surface modification of BTNPs has been done non-covalently in
aqueous solution by several dispersing agents such as 1,2-
distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(poly-
ethylene glycol)-5000] (DSPE-PEG) [79].
3.6. Quantum dots and up-conversion nanoparticles
QD use for neurostimulation has still primarily only been
explored in vitro [64,85,86,88,89]. Two main modalities of inter-
facing the QDs to neurons have been explored so far. The first
consists of directly attaching the QDs to the cellular membrane (i.e.,
as free-standing particles) either by their bare carboxylic residues
produced after their synthesis with mercaptoacetic acid (MAA), or
by conjugating antibodies or peptides to these carboxyl groups
[85,88] by EDC/NHS chemistry. As discussed in the previous sec-
tion, several issues have been encountered regarding the final fate
of the QDs in physiological conditions when used as free-standing
devices. Hence, the second way of modifying the QD interface with
the neurons involves the layer-by-layer (LBL) formation of a QD
substrate, on top of which neurons are cultured in a variety of forms
[86,89] in an attempt to solve some of the issues. A schematic
visualization of these LBL-QD constructs can be found in Bareket-
Keren et al. [64]. It should be noted that this second method re-
quires neurons to exist as a cell culture and will have limited
application in in vivo situations.
4. Biological barriers and tissue targeting
As exemplified by the previously listed literature, which surface
modifications and additional ligands are added onto the initial
transducing nanomaterial will highly depend on what type of
experimental application is being pursued. Therefore, classifying
the many types of ligands may be challenging, as they will probably
be appropriate for several design considerations. Conversely, many
design issues often could be solved bymore than one type of ligand.
As such, the following classification of ligands with potential for
in vivo use is discussed below, categorized by their primary
purpose.
4.1. Colloidal stability
Nanoscale neurostimulators in a biological environment need to
interact adequately with one another and with the environment,
particularly to avoid aggregation and undesired protein corona
effects [106]. Depending on the delivery method, the nano-
stimulators will need to be stable both in blood and the brain pa-
renchyma, with only the latter being necessary for intracranially
injected nanostimulators. Many comprehensive reviews already
discuss strategies for stabilizing nanomaterials both in blood
[107,108] and the CNS [109,110]. Particularly for neurostimulatory
applications, and as highlighted by Champagne et al. [109], these
stabilizing coatings often must offer the ability to further conjugate
other bioactive molecules. This is represented by the numerous
silica-shell [30,46,51] or PMA-shell [69,70,73] plus EDC/NHS
chemistry approaches used especially in vivo (Fig. 3A,B). Many of
the organic polymers discussed in the previous surface chemistry
section also provide this double functionality by simultaneously1292improving colloidal stability and acting as a substrate for other li-
gands. Interestingly, organically-modified silica nanoparticles have
already shown good interfacing properties with neurons in vivo
[111] which further suggests the use of silica as a stabilizing coating
in neurostimulation devices.
4.2. Immune clearance
Once inside the body, the fate of a given nanostimulator design
will be determined by physico-chemical phenomena such as sol-
ubility, size, superficial charge, etc. (i.e., parameters which can
reasonably be controlled at the synthesis stage). Another important
interactive consideration, as introduced above, is the formation of a
protein corona around the nanostimulators and how its dynamic
profile across biological barriers and environments will determine
the nanomaterial's functionality, biodistribution and therapeutic
(or in this case, stimulatory) effect [112,113]. Generally, the host's
immune systemwill identify and clear these nanomaterial-protein
moieties depending on how and which of the plasmatic proteins
adhere to them. The numerous immunological interactions
possible with protein-coated nanomaterials have been extensively
explored in specialized reviews [114,115]. PEG coatings are
frequently used to avoid immune recognition in constructs deliv-
ered systemically [116] but there have been reports of acquired
immune response against these PEG coatings after repeated
exposure [117]. While neurostimulatory nanomaterials can apply
immune evading strategies from other nanomedicines, thorough
studies of immune clearance of neurostimulatory nanomaterials
are not currently available. Current literature either i) bypasses
systemic delivery issues [30,46,51,69,70]; ii) explores coating al-
ternatives to PEG to solve immunologic issues related to systemic
delivery, but for non-stimulatory setups [118,119] or iii) explores
passive coatings which may be immunologically active (e.g. PEG or
poly (lactic-co-glycolic acid) (PLGA)) but in time-constrained setups
where this immune response is negligible [120e122]. Future
research will be needed to address how these and other coatings
affect the nanomaterials properties (e.g., transducing power, dis-
tribution, or aggregation) for neurostimulation purposes in more
depth [106].
4.3. BBB crossing and tissue penetration
Neurostimulatory applications in which nanomaterials are
delivered systemically must consider BBB crossing. Two strategies
can be considered here. The first is comprised of biochemically-
assisted approaches, which includes osmotic disruption of the
BBB [123] and surface functionalization via ligand-receptor in-
teractions, which can themselves involve endogenous molecules
(e.g., insulin, transferrin, antibodies, peptides) or chimeric mole-
cules [124e128]. The second strategy consists of physicochemical
interventions to transiently open the BBB, such as FUS in combi-
nation with microbubbles [129], or applied magnetic fields to force
the nanostimulators across the intact BBB [130,131]. Regarding
tissue penetration and diffusion, many specialized reviews have
explored how all of these passive and bioactive ligand combina-
tions, sizes and morphologies will condition the dynamic profile of
the nanomaterials within a tissue over time [132,133], albeit most
of the time this is studied in the context of tumors and cancer
theranostics and not for healthy, intact CNS tissues.
Stimulation of neural tissue in the peripheral nervous system
(PNS) is also possible with these nanomaterials, and numerous
existing reports are available which address their different chal-
lenges and limitations for this purpose compared to the CNS
[134,135]. For instance, engineering approaches are fundamentally
different (particularly surface chemistry) if the stimulating
Fig. 3. Reaction schemes for nanomaterial functionalization. AeB: Multi-layer functionalization of UCNPs with neutravidin; CeD: Gold nanoparticle growth and functionali-
zation with PEG and antibodies, reproduced with permission from Ref. [139]; EeF: Iron-oxide magnetic nanoparticle functionalization with a NHS-activated coat of PEG-oleic acid.
Reproduced with permission [30,105,139]. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)
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reach their target tissue (i.e., from blood to brain parenchyma).
Also, nanomaterials used to stimulate nerve activity in the PNS
often include regenerative capabilities since they are often inten-
ded to restore damaged nerve function [136]. Additionally, due to
the regenerative aim of these designs, studies in the PNS frequently
measure neural activity as cell growth (e.g., neurite growth) instead
of changes in action potentials per se [137]. However, successful
neurostimulation approaches have been reported using retinal
neurons, and since the retina can be considered both part of the
CNS or the PNS depending on the pursued application, these type of
studies can provide complementary insights to purely CNS and PNS
studies, for instance by testing novel nanoengineered devices
before using them in the CNS [138]. Overall, different challenges are
present when designing nanomaterials to achieve neuro-
stimulation in the CNS versus PNS tissues, and must be considered
before designing experimental setups and while consulting pub-
lished reports.
4.4. Cell/tissue-type specific targeting
The nanomaterial-cell interface is key to both application of the
transducing signal, as well as avoidance of off-target effects. In
general, two types of ligands can be considered. As described in the
previous BBB-crossing section, several metabolic routes can be
hijacked with either endogenous ligands (e.g., insulin, transferrin)
[128] or antibodies which target their receptors (Fig. 3C and D)
[125,139] in order to both cross the BBB and increase retention of
the nanomaterials. While greatly useful to target vascularly-
impaired tumors, or for the widespread delivery of1293neuroprotective drugs across the brain, this strategy lacks spatial
selectivity required to enable precise, localized neurostimulation.
Furthermore, in many neurostimulatory setups where there are no
physiological differences between desired and off-target neural
tissue, the bioactive ligands used to enable precise cell targeting
usually involve gene editing. Generally, these experiments are
performed either in transgenic animal models, or with wild-type
animals with neural tissue transfected locally, which then allows
the use of tailored antibodies that exclusively bind the nano-
materials to the transfected cells [15,30,67,69,70]. Regarding the
bioactive ligands themselves, they functionally act as recognition
ligands by epitope-paratope interactions (i.e., strong non-covalent
3-dimensional stereospecific interactions), and can be conven-
tional antibodies, aptamers, short peptides, or chimeric molecules
[140]. Another way to bypass the differential targeting of physio-
logically identical tissues and cells is the precise delivery of the
nanostimulators by stereotactic injection [17,69,70].
Once the nanodevices are attached to their cellular target, the
duration of this linkage will depend on a number of factors,
including the rate of turnover for proteins in the neuronal mem-
brane. If this turnover is too quick, only transient neurostimulation
will be achievable and long-term setups will not be feasible. The
main studies using antibody-conjugated nanomaterials presented
in this review [30,49,51,69,70] report continued response to stim-
ulation for up to a few days at most, and always less than a week.
Eventually, clinical uses will likely require longer retention times to
avoid repeated applications and off-site effects. The turnover rate of
neuronal proteins has significant effects on neuronal excitability
and plasticity, and these rates are known to change drastically
depending on the stimuli and environment of the neurons
D. Dominguez-Paredes, A. Jahanshahi and K.L. Kozielski Brain Stimulation 14 (2021) 1285e1297[141e143]. Neurostimulation unquestionably changes the physi-
ology of neurons, and the anchoring effect of attached antibodies
can also be expected to alter protein turnover rates. In summary,
future studies will have to explore in depth how these turnover
rates in neurostimulation setups are different to wild-type neurons
and how to use this information to optimally target the most du-
rable membrane molecules.
4.5. Tissue retention and clearance
A significant factor which will condition many aspects of any
clinical neurostimulatory approach is the length of time that the
nanostimulators remain at a functional concentration in the tar-
geted tissue. Ideally, the nanostimulators should remain active as
long as possible (thus avoiding repeated administrations) while
inflicting the least amount of cellular damage. Glial cells and, in
particular, microglia lead the response towards exogenous agents
in the brain parenchyma, and consequently, orchestrate the clear-
ance of any nanostimulators present. While the effects of some
nanomaterials on mammalian cells in vitro and in animal models
have been studied [144e146] there is currently a lack of research
exploring the same mechanisms in humans due to logistic and
ethical limitations. Models are in development to address this issue
[106]. Albeit few, there are some preliminary studies on the clear-
ance of other nanomaterials in the CNS of animal models. Super-
paramagnetic IONPs coated with dextran were injected into the
rat striatum and were gradually cleared out from the brain paren-
chyma at the injection site in about two weeks (presumably with
contribution of glial cells), with clearing times of up to 8 weeks
depending on nanoparticle concentration [144]. The literature
exploring how different nanomaterial ligands will condition this
glial clearance is also scarce, with existing reviews exploring them
in a case-by-case basis [147] for a myriad of different pathologies
and applications frequently outside the CNS. However, there are
some fundamental studies and reviews on the effects and clearance
of heavy metals such as titanium [145], iron [120,148], and other
metallic nanomaterials [146] in animal and in vitro models.
Therefore, long-term clearance and toxicity of these nanomaterials,
and especially how different surface ligands condition these phe-
nomena remain to be assessed. A thorough review of key factors
and limitations about this topic can be found in Ref. [146]. As a
related side note, recent reports [149,150] have found that
gadolinium-based contrast agents for MRI show retention and
deposition in the brain (as well as other organs). Intriguingly, so far
this has not shown to cause any neurological deficits, which sug-
gests that these nanoscale compound particles (3e350 nm in size)
must be somewhat well tolerated in the brain parenchyma, and
that tissue clearance must be slow or absent. Considering this was
an unexpected finding, it can be considered a valid reason to expect
other types of nanomaterials to also show a comparable clearance
and retention over time.
5. Conclusion, future perspectives, and pending issues
In this review, we have discussed current research avenues
aimed at developing novel nanoscale neurostimulator interfaces for
neurostimulatory purposes. While the field of neurostimulation via
nanomaterials is in its infancy, future studies will lead to more
innovative and translational technologies.
To achieve this, several technical challenges need to be
adequately addressed before these designs can be applied to living
human subjects. Namely, these challenges are the non-invasive
delivery of the nanostimulators to the target area, cell-type/
tissue-type specific modulation of neural elements, and external
control of the nanostimulators to provoke excitatory and inhibitory1294changes in neuronal activity. As this is a nascent technology, no
current nanostimulator design is able to meet these three re-
quirements simultaneously.
Most of the published research in this field is performed with
in vitro models [47,56,71,80], a practice which bypasses many bio-
logical constraints. In studies using in vivomodels, gene editing and
local nanoparticle administration also bypass some translational
considerations [17,30,67,69,70]. Additionally, nanomedicine is a
newly emerging field. Consequently, several of the discussed novel
transducing nanomaterials (e.g., BNNTs and TBTNPs) and surface
modifications are still relatively new and require further systematic
characterization before clinical translation is possible. This review
aims to provide a contextual background for these technical chal-
lenges, so that future studies about clinical neurostimulation can
benefit from the use of nanomaterials. In contrast, more conven-
tional nanomaterials have already proven their safety and effec-
tiveness in clinical trials and FDA-approved nanomedicine
formulations, albeit none of them (as of 2019) are capable of neu-
rostimulation (for reviews on the state of clinically-approved ma-
terials, see Refs. [19,151]). The majority of neurostimulatory
nanomaterial strategies presented in this review use more invasive,
local delivery into the target tissue, with some examples [130]
using systemic delivery. Local delivery may soon be replaced by
systemic delivery of the nanoparticles via the blood stream as
recent studies have shown that FUS or osmotic agents can tran-
siently make the BBB permeable to nanoparticles [123,129,152]. In
the future, these relatively non-invasive approaches will likely be
preferred to a stereotactic injection, but more work with in vivo
models will be needed to test the strengths and limitations of each
technique before moving onto human subjects.
Regarding cell-type or tissue-type specificity, many of the
studies listed have relied on the allocation of highly specific mo-
lecular constructs (e.g., exogenous ion channels) via gene editing
and later binding of the nanoparticles to these constructs by
matching antibodies. Ideally, more attempts should be made in the
future to target molecular motifs already present in wild-type
neurons. This will be a particularly challenging task since this
binding selectivity will depend on the available molecular differ-
ences between desired and off-target tissues, which may be scarce.
Future advancements in human gene editing may also help resolve
this issue if the addition of selective constructs becomes more
feasible and safe [33].
Cell-type specific neurostimulation is challenging when
considering the use of endogenous responsive molecules to trans-
duce the nanomaterial stimuli to the neurons. For thermally-
induced stimulation, a common strategy is to introduce the heat-
sensitive TRPV1 receptor via tissue genetic modification with
viral tools [40,49,66,67,70], or other related ion channels such as
TMEM16A [69]. For optogenetics and UCNP-based stimulation,
gene editing is used to achieve expression of light-sensitive opsins
[30,33]. Frequently, many of the reported gene editing in-
terventions also introduce other useful constructs simultaneously.
Among other uses, these help validate the causality of the neuro-
stimulation achieved since they usually have well known response
thresholds (e.g., the calcium indicator protein GCaMP6s). However,
these approaches are also entirely dependent on first applying
genetic engineering to human tissue. While wild-type neurons are
responsive to small changes in temperature, pressure, and other
cues from their environment, the magnitude of these responses
might not be large enough as to provoke the intended stimulation
only via intrinsic neuronal excitability. Consequently, more
research will be needed to assess how to minimize reliance on
transgenesis while still maintaining high responsiveness and
spatial selectivity in the evoked responses.
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production methods listed in this review are still at experimental
stages, and few of them have been produced at large or under
standardized guidelines. Eventually, as with all clinical products,
nanostimulators will require Good Manufacturing Practices (GMP)
to be made with appropriate quality standards. Different nano-
material sizes, surface modifications, and morphologies carry
different challenges and production costs. Thus, it remains to be
determined which neurostimulating nanomaterials are not only
effective in their design and transducing capabilities, but are also
feasible to be produced under GMP guidelines. Once again, inspi-
ration to tackle this problem can be drawn from existing reports
evaluating challenges in GMP production of nanomedicines and
other nanoscale products which are already closer to the clinic (for
an introduction on the topic, see Refs. [153,154]).
This review has examined the current state of untethered,
nanoscale neurostimulators with the intent of highlighting some of
the key barriers to clinical translation. While additional work will
be required to optimize nanomaterials for neurostimulation, par-
allel research in non-invasive delivery routes, toxicity, and tissue
specificity will help move this technology closer towards patient
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